Drug intelligence / Profile preview

GGW102

Development stage: Unknown
Lead developer: MingMed Biotechnology
Modality: Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Unknown (not Specified In Available Sources)

Overview

GGW102 is a small molecule immune checkpoint inhibitor developed as a novel veterinary chemical drug for the treatment of feline infectious peritonitis (FIP), an often fatal, immune-mediated disease in cats caused by certain strains of feline coronavirus (FCoV). As of January 2023, there were no effective treatments for FIP worldwide. GGW102 has been classified as a Class 1.1 novel veterinary chemical drug in China and has undergone Phase I and II clinical trials demonstrating good tolerability in domestic cats. A Phase III clinical trial is ongoing to further investigate its safety and efficacy[4].

Targets

Checkpoint (Immune checkpoints)

Beyond the preview

Go deeper on GGW102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GGW102.

Explore the full profile